• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Effective Induction of High-Titer Antibodies by Viral Vector Vaccines

sharon sanders

Editor-in-Chief & President
Brief Communication abstract

<hr class="separator"> Nature Medicine 14, 819 - 821 (2008)
Published online: 27 July 2008 | <abbr title="Digital Object Identifier">doi</abbr>:10.1038/nm.1850
Effective induction of high-titer antibodies by viral vector vaccines

Simon J Draper<sup>1</sup>, Anne C Moore<sup>1,</sup><sup>5</sup>, Anna L Goodman<sup>1</sup>, Carole A Long<sup>2</sup>, Anthony A Holder<sup>3</sup>, Sarah C Gilbert<sup>1</sup>, Fergal Hill<sup>4</sup> & Adrian V S Hill<sup>1</sup>
Top of pageProtein-in-adjuvant vaccines have shown limited success against difficult diseases such as blood-stage malaria. Here we show that a recombinant adenovirus?poxvirus prime-boost immunization regime (known to induce strong T cell immunogenicity) can also induce very strong antigen-specific antibody responses, and we identify a simple complement-based adjuvant to further enhance immunogenicity. Antibodies induced against a blood-stage malaria antigen by this viral vector platform are highly effective against Plasmodium yoelii parasites in mice and against Plasmodium falciparum in vitro.

Top of page<hr class="separator">
  1. The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK.
  2. Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, US National Institutes of Health, 12735 Twinbrook Parkway, Rockville, Maryland 20852, USA.
  3. Division of Parasitology, National Institute for Medical Research, The Ridgeway, Mill Hill, London, NW7 1AA, UK.
  4. Imaxio, 181-203 Avenue Jean Jaur?s, 69007 Lyon, France.
  5. Current address: School of Pharmacy, Cavanagh Pharmacy Building, University College Cork, Cork, Ireland.
Correspondence to: Simon J Draper<sup>1</sup> e-mail: simon.draper@ndm.ox.ac.uk


http://www.nature.com/nm/journal/v14/n8/abs/nm.1850.html

 
Back
Top